Regen Biopharma Inc (RGBAD)

[trazbull]

New 8k...hmmmmm:

Item 8.01 Other Events

On July 5, 2018 and July 3, 2018 respectively David Koos and Harry Lander assigned to Regen Biopharma, Inc. (“Regen”) their entire right , title and interest throughout the world in the inventions, improvements and all patent applications that are subject of an application for patent protection filed with the United States Patent and Trademark Office on June 14, 2018 entitled “Small Molecule Agonists and Antagonists of NR2F6 Activity” The abovementioned application relates to agonists and antagonists of nuclear receptor activity, specifically to the modulation ofNR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described within the application. David Koos currently serves as Chairman of the Board of Directors and Chief Executive Officer of Regen. Harry Lander currently serves as President and Chief Scientific Officer of Regen.

2




SIGNATURE





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



REGEN BIOPHARMA, INC.

Dated: 7/05/2018 By: /s/ David Koos
David Koos
Chief Executive Officer